CGP 25454A is primarily used in research settings as a selective inhibitor of monoamine oxidase A (MAO-A). It is particularly valuable in studies focused on understanding the role of MAO-A in neurological and psychiatric disorders, such as depression and anxiety. By inhibiting MAO-A, it helps researchers explore the regulation of neurotransmitters like serotonin, norepinephrine, and dopamine, which are critical for mood and behavior. Additionally, CGP 25454A is utilized in preclinical studies to investigate the potential therapeutic effects of MAO-A inhibition in various mental health conditions. Its selectivity makes it a useful tool for distinguishing the specific contributions of MAO-A from MAO-B in biological processes.